Biogen Inc. (0R1B.L)
USD 150.06
(-0.94%)
USD 150.06
(-0.94%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 6.28 Billion USD | 96.84% |
| 2022 | 3.19 Billion USD | -40.2% |
| 2021 | 5.34 Billion USD | -17.78% |
| 2020 | 6.49 Billion USD | 88.11% |
| 2019 | 3.45 Billion USD | -26.7% |
| 2018 | 4.71 Billion USD | 8.04% |
| 2017 | 4.36 Billion USD | 4.18% |
| 2016 | 4.18 Billion USD | -19.7% |
| 2015 | 5.21 Billion USD | 941.26% |
| 2014 | -619.72 Million USD | -9240.27% |
| 2013 | -6.63 Million USD | -101.16% |
| 2012 | 570.05 Million USD | 3.73% |
| 2011 | 549.55 Million USD | 23.79% |
| 2010 | 443.93 Million USD | -14.31% |
| 2009 | 518.08 Million USD | 5.58% |
| 2008 | 490.71 Million USD | -45.68% |
| 2007 | 903.31 Million USD | 259.97% |
| 2006 | -564.68 Million USD | -7.62% |
| 2005 | -524.72 Million USD | -181.88% |
| 2004 | 640.86 Million USD | 11.96% |
| 2003 | 572.42 Million USD | 20434.64% |
| 2002 | -2.81 Million USD | -110.01% |
| 2001 | 28.11 Million USD | -53.59% |
| 2000 | 60.58 Million USD | 7.91% |
| 1999 | 56.14 Million USD | 54.22% |
| 1998 | 36.4 Million USD | 71.77% |
| 1997 | 21.19 Million USD | 399.95% |
| 1996 | 4.23 Million USD | 137.59% |
| 1995 | -11.27 Million USD | 79.38% |
| 1994 | -54.68 Million USD | 26.6% |
| 1993 | -74.5 Million USD | 13.27% |
| 1992 | -85.9 Million USD | -51.77% |
| 1991 | -56.6 Million USD | -349.21% |
| 1990 | -12.6 Million USD | 62.05% |
| 1989 | -33.2 Million USD | 32.93% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 5.87 Billion USD | -6.62% |
| 2024 Q2 | 4.94 Billion USD | -15.81% |
| 2024 Q3 | 3.2 Billion USD | 0.16% |
| 2023 Q3 | 5.42 Billion USD | 36.67% |
| 2023 Q2 | 3.97 Billion USD | 7.0% |
| 2023 FY | 6.28 Billion USD | 96.84% |
| 2023 Q1 | 3.71 Billion USD | 16.18% |
| 2023 Q4 | 6.28 Billion USD | 15.86% |
| 2022 Q1 | 5.83 Billion USD | 9.29% |
| 2022 FY | 3.19 Billion USD | -40.2% |
| 2022 Q4 | 3.19 Billion USD | 7.99% |
| 2022 Q3 | 2.95 Billion USD | -39.68% |
| 2022 Q2 | 4.9 Billion USD | -15.99% |
| 2021 FY | 5.34 Billion USD | -17.78% |
| 2021 Q1 | 6.42 Billion USD | -1.04% |
| 2021 Q4 | 5.34 Billion USD | -12.1% |
| 2021 Q3 | 6.07 Billion USD | 3.16% |
| 2021 Q2 | 5.89 Billion USD | -8.38% |
| 2020 Q2 | 5.45 Billion USD | 44.5% |
| 2020 Q4 | 6.49 Billion USD | 15.83% |
| 2020 Q3 | 5.6 Billion USD | 2.85% |
| 2020 FY | 6.49 Billion USD | 88.11% |
| 2020 Q1 | 3.77 Billion USD | 9.27% |
| 2019 Q4 | 3.45 Billion USD | -14.09% |
| 2019 Q3 | 4.02 Billion USD | -13.51% |
| 2019 Q1 | 4.13 Billion USD | -12.22% |
| 2019 Q2 | 4.64 Billion USD | 12.38% |
| 2019 FY | 3.45 Billion USD | -26.7% |
| 2018 FY | 4.71 Billion USD | 8.04% |
| 2018 Q2 | 4.67 Billion USD | 156.85% |
| 2018 Q3 | 3.54 Billion USD | -24.24% |
| 2018 Q4 | 4.71 Billion USD | 32.94% |
| 2018 Q1 | 1.82 Billion USD | -58.24% |
| 2017 Q4 | 4.36 Billion USD | -0.66% |
| 2017 Q2 | 5.34 Billion USD | -4.4% |
| 2017 Q1 | 5.59 Billion USD | 33.54% |
| 2017 FY | 4.36 Billion USD | 4.18% |
| 2017 Q3 | 4.39 Billion USD | -17.85% |
| 2016 Q1 | 5.4 Billion USD | 3.77% |
| 2016 Q2 | 5.18 Billion USD | -4.23% |
| 2016 Q3 | 4.44 Billion USD | -14.21% |
| 2016 FY | 4.18 Billion USD | -19.7% |
| 2016 Q4 | 4.18 Billion USD | -5.82% |
| 2015 Q2 | -702.6 Million USD | 21.42% |
| 2015 Q3 | 2.44 Billion USD | 448.05% |
| 2015 Q1 | -894.12 Million USD | -44.28% |
| 2015 Q4 | 5.21 Billion USD | 113.19% |
| 2015 FY | 5.21 Billion USD | 941.26% |
| 2014 Q2 | -273.72 Million USD | -16.95% |
| 2014 Q3 | -599.08 Million USD | -118.87% |
| 2014 Q1 | -234.03 Million USD | -3427.34% |
| 2014 FY | -619.72 Million USD | -9240.27% |
| 2014 Q4 | -619.72 Million USD | -3.45% |
| 2013 Q3 | 270.46 Million USD | -19.76% |
| 2013 FY | -6.63 Million USD | -101.16% |
| 2013 Q4 | -6.63 Million USD | -102.45% |
| 2013 Q2 | 337.06 Million USD | 33.84% |
| 2013 Q1 | 251.84 Million USD | -55.82% |
| 2012 Q4 | 570.05 Million USD | -13.62% |
| 2012 FY | 570.05 Million USD | 3.73% |
| 2012 Q1 | 781.23 Million USD | 42.16% |
| 2012 Q2 | 637.8 Million USD | -18.36% |
| 2012 Q3 | 659.92 Million USD | 3.47% |
| 2011 Q1 | 409.71 Million USD | -7.71% |
| 2011 Q3 | 488.92 Million USD | -1.71% |
| 2011 FY | 549.55 Million USD | 23.79% |
| 2011 Q4 | 549.55 Million USD | 12.4% |
| 2011 Q2 | 497.44 Million USD | 21.41% |
| 2010 Q1 | 455.75 Million USD | -12.03% |
| 2010 FY | 443.93 Million USD | -14.31% |
| 2010 Q4 | 443.93 Million USD | -2.07% |
| 2010 Q3 | 453.31 Million USD | 26.32% |
| 2010 Q2 | 358.85 Million USD | -21.26% |
| 2009 Q3 | 515.5 Million USD | 64.44% |
| 2009 Q4 | 518.08 Million USD | 0.5% |
| 2009 FY | 518.08 Million USD | 5.58% |
| 2009 Q1 | 345.29 Million USD | -29.63% |
| 2009 Q2 | 313.5 Million USD | -9.21% |
| 2008 Q1 | 384.79 Million USD | -57.4% |
| 2008 Q4 | 490.71 Million USD | 1070.01% |
| 2008 Q3 | 41.94 Million USD | -92.81% |
| 2008 FY | 490.71 Million USD | -45.68% |
| 2008 Q2 | 583.13 Million USD | 51.55% |
| 2007 FY | 903.31 Million USD | 259.97% |
| 2007 Q1 | -719.74 Million USD | -27.46% |
| 2007 Q2 | -1.54 Billion USD | -115.12% |
| 2007 Q3 | 1.12 Billion USD | 172.52% |
| 2007 Q4 | 903.31 Million USD | -19.56% |
| 2006 Q1 | -491.88 Million USD | 6.26% |
| 2006 Q2 | -300.57 Million USD | 38.89% |
| 2006 Q3 | -369.52 Million USD | -22.94% |
| 2006 FY | -564.68 Million USD | -7.62% |
| 2006 Q4 | -564.68 Million USD | -52.82% |
| 2005 Q4 | -524.72 Million USD | -106.94% |
| 2005 Q1 | 569.99 Million USD | -11.06% |
| 2005 Q2 | -595.99 Million USD | -204.56% |
| 2005 Q3 | -253.56 Million USD | 57.45% |
| 2005 FY | -524.72 Million USD | -181.88% |
| 2004 FY | 640.86 Million USD | 11.96% |
| 2004 Q3 | 666.68 Million USD | 74.11% |
| 2004 Q1 | 558.5 Million USD | -2.43% |
| 2004 Q2 | 382.91 Million USD | -31.44% |
| 2004 Q4 | 640.86 Million USD | -3.87% |
| 2003 Q3 | -75.31 Million USD | -237.76% |
| 2003 Q2 | -22.29 Million USD | -205.4% |
| 2003 FY | 572.42 Million USD | 20434.64% |
| 2003 Q4 | 572.42 Million USD | 860.07% |
| 2003 Q1 | 21.15 Million USD | 851.51% |
| 2002 FY | -2.81 Million USD | -110.01% |
| 2002 Q3 | 22.23 Million USD | -52.38% |
| 2002 Q2 | 46.68 Million USD | 387.05% |
| 2002 Q1 | -16.26 Million USD | -157.84% |
| 2002 Q4 | -2.81 Million USD | -112.66% |
| 2001 Q3 | 42.44 Million USD | 56.69% |
| 2001 Q2 | 27.08 Million USD | -64.11% |
| 2001 Q1 | 75.47 Million USD | 24.57% |
| 2001 FY | 28.11 Million USD | -53.59% |
| 2001 Q4 | 28.11 Million USD | -33.75% |
| 2000 Q4 | 60.58 Million USD | 239.16% |
| 2000 FY | 60.58 Million USD | 7.91% |
| 2000 Q1 | -45.88 Million USD | -181.73% |
| 2000 Q3 | 17.86 Million USD | 238.0% |
| 2000 Q2 | -12.94 Million USD | 71.79% |
| 1999 FY | 56.14 Million USD | 54.22% |
| 1999 Q3 | -14.9 Million USD | -322.39% |
| 1999 Q4 | 56.14 Million USD | 476.79% |
| 1999 Q2 | 6.7 Million USD | 122.11% |
| 1999 Q1 | -30.3 Million USD | -183.23% |
| 1998 Q1 | 23.6 Million USD | 11.36% |
| 1998 Q4 | 36.4 Million USD | 405.91% |
| 1998 Q3 | -11.9 Million USD | -267.61% |
| 1998 Q2 | 7.1 Million USD | -69.92% |
| 1998 FY | 36.4 Million USD | 71.77% |
| 1997 Q3 | 5.8 Million USD | 241.46% |
| 1997 Q1 | -30.7 Million USD | -824.23% |
| 1997 Q2 | -4.1 Million USD | 86.64% |
| 1997 Q4 | 21.19 Million USD | 265.4% |
| 1997 FY | 21.19 Million USD | 399.95% |
| 1996 Q4 | 4.23 Million USD | 571.0% |
| 1996 Q1 | 9.1 Million USD | 180.7% |
| 1996 Q2 | 2.6 Million USD | -71.43% |
| 1996 Q3 | -900 Thousand USD | -134.62% |
| 1996 FY | 4.23 Million USD | 137.59% |
| 1995 Q4 | -11.27 Million USD | 48.03% |
| 1995 Q3 | -21.7 Million USD | 0.0% |
| 1995 Q2 | -21.7 Million USD | 50.0% |
| 1995 FY | -11.27 Million USD | 79.38% |
| 1995 Q1 | -43.4 Million USD | 20.63% |
| 1994 Q4 | -54.68 Million USD | 16.52% |
| 1994 Q1 | -52.7 Million USD | 29.26% |
| 1994 Q2 | -39.1 Million USD | 25.81% |
| 1994 Q3 | -65.5 Million USD | -67.52% |
| 1994 FY | -54.68 Million USD | 26.6% |
| 1993 Q1 | -47.4 Million USD | 44.82% |
| 1993 Q2 | -77.2 Million USD | -62.87% |
| 1993 Q4 | -74.5 Million USD | 0.53% |
| 1993 Q3 | -74.9 Million USD | 2.98% |
| 1993 FY | -74.5 Million USD | 13.27% |
| 1992 Q4 | -85.9 Million USD | -13.93% |
| 1992 FY | -85.9 Million USD | -51.77% |
| 1992 Q2 | -36.8 Million USD | 5.15% |
| 1992 Q3 | -75.4 Million USD | -104.89% |
| 1992 Q1 | -38.8 Million USD | 31.45% |
| 1991 Q3 | -20.4 Million USD | -482.86% |
| 1991 FY | -56.6 Million USD | -349.21% |
| 1991 Q2 | -3.5 Million USD | 79.53% |
| 1991 Q4 | -56.6 Million USD | -177.45% |
| 1991 Q1 | -17.1 Million USD | -35.71% |
| 1990 Q4 | -12.6 Million USD | 13.1% |
| 1990 FY | -12.6 Million USD | 62.05% |
| 1990 Q2 | -17.2 Million USD | -20.28% |
| 1990 Q1 | -14.3 Million USD | 56.93% |
| 1990 Q3 | -14.5 Million USD | 15.7% |
| 1989 Q4 | -33.2 Million USD | -2.79% |
| 1989 Q3 | -32.3 Million USD | 0.0% |
| 1989 FY | -33.2 Million USD | 32.93% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 7318.307% |
| Dynavax Technologies Corporation | 106.63 Million USD | -5797.032% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 18855.928% |
| Perrigo Company plc | 3.32 Billion USD | -89.287% |
| Illumina, Inc. | 1.21 Billion USD | -417.982% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 76.571% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 5621.477% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 23.639% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 51.083% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -4234.487% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 23304.059% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -87395.478% |
| Waters Corporation | 1.96 Billion USD | -220.76% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 88667.606% |
| Evolus, Inc. | 63.7 Million USD | -9770.503% |
| Adicet Bio, Inc. | -142 Million USD | 4528.131% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 69846.007% |
| bluebird bio, Inc. | 108.57 Million USD | -5691.878% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -1270.899% |
| FibroGen, Inc. | 56.76 Million USD | -10977.387% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -449.197% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -90144.423% |
| Homology Medicines, Inc. | 18.43 Million USD | -34006.959% |
| Geron Corporation | 14.76 Million USD | -42500.772% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | -296.656% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -3074.867% |
| Myriad Genetics, Inc. | 88.1 Million USD | -7037.684% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 11690.055% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 5744.692% |
| Zoetis Inc. | 4.76 Billion USD | -32.052% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 62539.678% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | -199.734% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -1560.286% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 165.75% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 43253.308% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -496.458% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -19621.813% |
| Verastem, Inc. | -37.27 Million USD | 16968.662% |
| Nektar Therapeutics | 210.24 Million USD | -2891.01% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 3246.967% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 17185.915% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -549.364% |
| OPKO Health, Inc. | 230.68 Million USD | -2625.949% |
| Exelixis, Inc. | -73.05 Million USD | 8708.214% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -3446.701% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 4744.239% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 4263.775% |
| uniQure N.V. | -102.95 Million USD | 6208.051% |
| Imunon, Inc. | -4.69 Million USD | 133914.316% |
| Blueprint Medicines Corporation | 702.83 Million USD | -794.704% |
| Insmed Incorporated | 721.62 Million USD | -771.414% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | -355.384% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 20243.832% |
| TG Therapeutics, Inc. | 17.86 Million USD | -35104.904% |
| Incyte Corporation | -3.17 Billion USD | 298.051% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -721.141% |